wb 4101 has been researched along with Prostatic Hyperplasia in 3 studies
N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine bearing a [(2',6'-dimethoxyphenoxy)ethylamino]methyl group at position 2. An alpha1A-adrenergic selective antagonist.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kenny, B | 1 |
| Ballard, S | 1 |
| Blagg, J | 1 |
| Fox, D | 1 |
| Chapple, CR | 1 |
| Burt, RP | 1 |
| Andersson, PO | 1 |
| Greengrass, P | 1 |
| Wyllie, M | 1 |
| Marshall, I | 1 |
| Muramatsu, I | 1 |
| Oshita, M | 1 |
| Ohmura, T | 1 |
| Kigoshi, S | 1 |
| Akino, H | 1 |
| Gobara, M | 1 |
| Okada, K | 1 |
1 review available for wb 4101 and Prostatic Hyperplasia
| Article | Year |
|---|---|
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlle | 1997 |
2 other studies available for wb 4101 and Prostatic Hyperplasia
| Article | Year |
|---|---|
Alpha 1-adrenoceptor subtypes in the human prostate.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Aminoquinolines; Dioxanes; Dose-Response Rela | 1994 |
Pharmacological characterization of alpha 1-adrenoceptor subtypes in the human prostate: functional and binding studies.
Topics: Adrenergic alpha-Antagonists; Binding, Competitive; Clonidine; Dioxanes; Dose-Response Relationship, | 1994 |